RT Journal Article
SR Electronic
T1 The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world data from three hospitals in Wuhan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.11.20056523
DO 10.1101/2020.04.11.20056523
A1 Qibin Liu
A1 Xuemin Fang
A1 Lu Tian
A1 Ungil Chung
A1 Xianxiang Chen
A1 Ke Wang
A1 Dan Li
A1 Xiyong Dai
A1 Qi Zhu
A1 Feng Xu
A1 Lei Shen
A1 Bing Wang
A1 Li Yao
A1 Peng Peng
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.11.20056523.abstract
AB BACKGROUND The worldwide COVID-19 pandemic develops rapidly. There is a pressing need to find an effective therapy.METHODS We have assembled a cohort consisting 504 hospitalized COVID-19. Information of patients’ characteristics and antiviral medication use during hospital stay is collected. The study objective is to evaluate the treatment efficacy of selected antiviral medications on mortality and lesion absorption based on chest CT scan.RESULTS The overall mortality rate was 15.67% in the cohort. Older age, lower SpO2 level, bigger lesion, early admission data, and the presence of pre-existing conditions were associated with higher mortality. After adjusting for sex, pre-existing condition, age, SpO2, lesion size, admission data, hospital, and anti-viral medications use, Arbidol and Oseltamivir use is associated with a reduction in mortality. The OR is 0.183 (95% CI, 0.075 to 0.446; p<0.001) for Arbidol and 0.220 (95% CI, 0.069 to 0.707; p=0.011) for Oseltamivir. Compared with patients taking neither Arbidol nor Oseltamivir, the OR is 0.253 (95% CI, 0.064 to 1.001; p=0.050) for patients taking Oseltamivir only; 0.190 (95% CI, 0.076 to 0.473; p<0.001) for patients taking Arbidol only; and 0.030 (95% CI, 0.003 to 0.310; p=0.003) for patients taking both, after adjusting for patients’ characteristics and Lopinavir/Ritonavir use. Similarly, Arbidol is also associated with faster lesion absorption after adjusting for patient’s characteristics as well as Oseltamivir and Lopinavir/Ritonavir use.CONCUSIONS Arbidol is able to substantially associated with a reduction in mortality among hospitalized COVID-19 patients. The combination of Arbidol and Oselmativir may further associated with a reduction in mortality. There is no proven treatment benefit of Lopinavir/Ritonavir.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors report no funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.